Future oncology最新文献_第2页

Patient, caregiver experiences in metastatic castration-resistant prostate cancer: insights from a multi-national survey. 转移性去势抵抗性前列腺癌患者和护理人员的经历：来自多国调查的见解。

IF 3 4区医学

Future oncology Pub Date : 2025-06-02 DOI: 10.1080/14796694.2025.2510890

Ruhee Jain, Rob Seebold, Jonathan Weiser, Emma Smith, Andrea Stevens, Neerav Monga, Katherine Bevans, Matthew Pagano, Katie Pascoe

{"title":"Patient, caregiver experiences in metastatic castration-resistant prostate cancer: insights from a multi-national survey.","authors":"Ruhee Jain, Rob Seebold, Jonathan Weiser, Emma Smith, Andrea Stevens, Neerav Monga, Katherine Bevans, Matthew Pagano, Katie Pascoe","doi":"10.1080/14796694.2025.2510890","DOIUrl":"https://doi.org/10.1080/14796694.2025.2510890","url":null,"abstract":"Objective: Patients with metastatic castration-resistant prostate cancer (mCRPC) and caregivers were surveyed to understand their attitudes, emotions, and experiences with the disease, its treatments, and their willingness to explore genetic testing.Methods: A non-interventional, cross-sectional, online, quantitative-qualitative survey was conducted from 17-February to 9March 2022 among patients (≥21-years old) with mCRPC (diagnosis for ≥3-months) and caregivers.Results: A total of 221 patients with mCRPC and 159 caregivers from USA, France, Germany, Canada, Spain, China, and Brazil were surveyed. mCRPC impacts mood, emotional and mental health (50-77%), sleep (48-68%), career goals (48-80%), and social activities (46-65%). Primary symptoms/side effects are urination issues (trouble urinating: 33-60%; painful/burning urination: 32-50%, frequent urination: 27-50%) and sexual dysfunction (lower libido: 10-57%), which impact romantic relationships. Caregivers often spouses or partners, provide practical, financial, and emotional support, averaging 11 hours/week of providing care. Patients face high treatment and pill burden (7-12 pills/day) and prefer simpler treatment regimens. Hope motivates patients and genetic testing is one such avenue of hope.Conclusion: mCRPC is a life-changing diagnosis with physical, psychological, and financial burdens. By encouraging early genetic testing and fostering patient-centered conversation, HCPs can provide personalized care for optimized treatment outcomes in mCRPC.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-14"},"PeriodicalIF":3.0,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144198920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

rechARge: a randomized phase III trial of the androgen receptor ligand-directed degrader, BMS-986365, vs investigator's choice in patients with mCRPC. rechARge：雄激素受体配体定向降降剂BMS-986365与研究者选择的mCRPC患者的随机III期试验

IF 3 4区医学

Future oncology Pub Date : 2025-06-02 DOI: 10.1080/14796694.2025.2502318

Kim Nguyen Chi, Rana R McKay, Shahneen Sandhu, Jose A Arranz, Philippe Barthélémy, Boris Hadaschik, Nobuaki Matsubara, Neal D Shore, Dingwei Ye, Teresa Cascella, Irina Irincheeva, Stephanie Kreiser, Antoine Thiery-Vuillemin, Dana E Rathkopf

{"title":"rechARge: a randomized phase III trial of the androgen receptor ligand-directed degrader, BMS-986365, vs investigator's choice in patients with mCRPC.","authors":"Kim Nguyen Chi, Rana R McKay, Shahneen Sandhu, Jose A Arranz, Philippe Barthélémy, Boris Hadaschik, Nobuaki Matsubara, Neal D Shore, Dingwei Ye, Teresa Cascella, Irina Irincheeva, Stephanie Kreiser, Antoine Thiery-Vuillemin, Dana E Rathkopf","doi":"10.1080/14796694.2025.2502318","DOIUrl":"https://doi.org/10.1080/14796694.2025.2502318","url":null,"abstract":"There is an ongoing need for efficacious, life-prolonging therapies for males with metastatic castration-resistant prostate cancer (mCRPC). mCRPC that progresses after treatment with androgen receptor pathway inhibitors (ARPIs) may still be driven by AR signaling. BMS-986365 is a heterobifunctional, orally bioavailable ligand-directed degrader that targets the AR through a first-in-class dual mechanism of AR degradation and antagonism. Here, we present the study design of rechARge, a phase III, randomized, multicenter, adaptive, two-part, open-label trial evaluating BMS-986365 versus investigator's choice of therapy comprising either docetaxel or a switch to an alternative ARPI (abiraterone or enzalutamide) in patients with mCRPC whose disease has progressed after treatment with one prior ARPI. The primary study objective is to compare the efficacy and safety of BMS-986365 versus investigator's choice of therapy. Approximately 960 patients will be enrolled.Clinical trial registration: www.clinicaltrials.gov identifier is NCT06764485.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-7"},"PeriodicalIF":3.0,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144208408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The effect of postmastectomy radiotherapy after neoadjuvant chemotherapy in patients with breast cancer: a meta-analysis. 乳腺癌患者新辅助化疗后乳房切除术放疗的效果：一项荟萃分析。

IF 3 4区医学

Future oncology Pub Date : 2025-06-02 DOI: 10.1080/14796694.2025.2505372

Aishan Zou, Liuyi Li, Yang Guo, Cuiwei Zhang

{"title":"The effect of postmastectomy radiotherapy after neoadjuvant chemotherapy in patients with breast cancer: a meta-analysis.","authors":"Aishan Zou, Liuyi Li, Yang Guo, Cuiwei Zhang","doi":"10.1080/14796694.2025.2505372","DOIUrl":"https://doi.org/10.1080/14796694.2025.2505372","url":null,"abstract":"Background: Recent advancements in NAC efficacy have sparked considerable debate regarding the role of postmastectomy radiation therapy (PMRT) in breast cancer treatment.Methods: A comprehensive search of PubMed, Embase, and Cochrane databases was conducted to identify all relevant studies examining the prognostic significance of PMRT in breast cancer patients. The incidence of adverse events was aggregated to determine the correlation between PMRT and patient survival outcomes.Results: The current meta-analysis included 15 eligible studies. Patients who received PMRT numbered 42,289, while 23,199 did not receive these treatments. No significant difference was observed between PMRT and OS (pooled RR 0.93; 95% CI 0.83-1.04) or DMFS (pooled RR 1.12; 95% CI 0.99-1.28) in predicting breast cancer outcomes. PMRT was associated with improved DFS in patients with lymphovascular invasion (LVI) (pooled RR 0.33; 95% CI 0.19-0.57). The meta-analysis found no significant correlation between PMRT and OS in patients with pathological complete remission (pCR) (HR 0.86; 95% CI 0.68-1.07).Conclusion: No significant difference was observed between PMRT and OS. While PMRT did not improve overall survival in the entire group, our subgroup analyses suggest selective benefit for non-pCR or LVI positive patients. These findings may aid in the clinical decision-making process.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-10"},"PeriodicalIF":3.0,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144198921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The impacts of physical factors on huge hepatocellular carcinoma treated by transarterial chemoembolization combined with radiotherapy. 物理因素对经动脉化疗栓塞联合放射治疗巨大肝细胞癌的影响

IF 3 4区医学

Future oncology Pub Date : 2025-06-01 Epub Date: 2024-09-12 DOI: 10.1080/14796694.2024.2395801

Juanjuan Shen, Nanbao Zhong, Zhonghua Chen, Danyu Ma, Jianhai Lin

引用次数: 0

A critical call to action for transformative cancer care in transgender, non-binary, and intersex populations. 对跨性别、非双性和双性人群进行变革性癌症治疗的关键行动呼吁。

IF 3 4区医学

Future oncology Pub Date : 2025-06-01 Epub Date: 2025-04-25 DOI: 10.1080/14796694.2025.2497746

Sara G Bybee, Lauren Catlett, Nicole Fleming, N F N Scout

引用次数: 0

Plain language summary and patient perspective of the European Society for Medical Oncology expert consensus statements on treating EGFR-positive non-small-cell lung cancer. 欧洲肿瘤内科学会关于治疗表皮生长因子受体阳性非小细胞肺癌的专家共识声明的通俗语言摘要和患者观点。

IF 3 4区医学

Future oncology Pub Date : 2025-06-01 Epub Date: 2023-03-20 DOI: 10.2217/fon-2022-1213

Rachel Jenkins, Joanne Walker, Upal Basu Roy

引用次数: 0

Real-world use, effectiveness, and safety of second-line lurbinectedin monotherapy in small cell lung cancer. 鲁比丁二线单药治疗小细胞肺癌的实际应用、有效性和安全性。

IF 3 4区医学

Future oncology Pub Date : 2025-06-01 Epub Date: 2025-05-26 DOI: 10.1080/14796694.2025.2499441

Apar Kishor Ganti, Ralph B D'Agostino, Victoria Allan, Patricia Prince, Adina Estrin, Nileesa Gautam, Anne Boccuti, Badri Rengarajan, Wenyan Li, Yanyan Cao, Xiaozhou Fan, Elizabeth M Poole

{"title":"Real-world use, effectiveness, and safety of second-line lurbinectedin monotherapy in small cell lung cancer.","authors":"Apar Kishor Ganti, Ralph B D'Agostino, Victoria Allan, Patricia Prince, Adina Estrin, Nileesa Gautam, Anne Boccuti, Badri Rengarajan, Wenyan Li, Yanyan Cao, Xiaozhou Fan, Elizabeth M Poole","doi":"10.1080/14796694.2025.2499441","DOIUrl":"10.1080/14796694.2025.2499441","url":null,"abstract":"Aim: Assess real-world outcomes of lurbinectedin and other second-line treatments (OST) in adults with small cell lung cancer that progressed on/after chemotherapy.Patients & methods: US-based electronic medical data from Flatiron Health (01/01/2013-03/31/2022) were used. Baseline characteristics, including chemotherapy-free interval (CTFI), in patients receiving lurbinectedin or OST were balanced using propensity score (PS) overlap weighting.Results: Before PS-weighting, median (95% confidence interval [CI]) real-world progression-free survival (rwPFS) was 2.46 months (2.07-2.73), and real-world response rate (rwRR) was 27.5% (23.1-32.4) in 374 eligible lurbinectedin-treated patients. After PS-weighting, median rwPFS was 2.73 months (2.33-3.32) and 2.53 months (2.23-2.99) in 291 lurbinectedin-treated patients and 261 OST-treated patients, respectively; rwRR was 30.9% and 31.8% (relative risk, 0.97). Lurbinectedin demonstrated numerically improved median rwPFS (3.61 versus 3.02 months) and rwRR (38.7% versus 36.1%) versus OST in patients with CTFI ≥90 days but not in patients with CTFI <90 days (2.00 months both; 20.5% versus 26.1%). Lurbinectedin-treated patients reported less grade ≥3 thrombocytopenia (11.7%) and anemia (6.5%) versus OST (27.2% and 20.3%, respectively); prevalence by CTFI status were similar.Conclusion: Lurbinectedin demonstrated comparable real-world effectiveness with OST with a favorable safety profile; however, these findings are limited by small sample size.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1675-1685"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144150260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-world treatment of large B-cell lymphoma with chimeric antigen receptor T-cell therapy after loncastuximab tesirine: a plain language summary. loncastuximab tesirine后嵌合抗原受体t细胞治疗大b细胞淋巴瘤的实际治疗：一个简单的语言总结。

IF 3 4区医学

Future oncology Pub Date : 2025-06-01 Epub Date: 2025-05-30 DOI: 10.1080/14796694.2025.2492543

Mehdi Hamadani, Melanie Lucero, Jakob D DeVos, Lei Chen

引用次数: 0

Impact of social determinants of health on treatment patterns and outcomes in multiple myeloma. 健康的社会决定因素对多发性骨髓瘤治疗模式和结果的影响

IF 3 4区医学

Future oncology Pub Date : 2025-06-01 Epub Date: 2025-05-12 DOI: 10.1080/14796694.2025.2498878

Natalie Boytsov, Jasjit K Multani, Zifan Zhou, Nirali Kotowsky, Amanda Bolgioni-Smith, Tianyao Huo, Queenie Paltanwale, Simon McNamara, Chi-Chang Chen

{"title":"Impact of social determinants of health on treatment patterns and outcomes in multiple myeloma.","authors":"Natalie Boytsov, Jasjit K Multani, Zifan Zhou, Nirali Kotowsky, Amanda Bolgioni-Smith, Tianyao Huo, Queenie Paltanwale, Simon McNamara, Chi-Chang Chen","doi":"10.1080/14796694.2025.2498878","DOIUrl":"10.1080/14796694.2025.2498878","url":null,"abstract":"Aims: Evaluate treatment and outcomes by social determinants of health (SDoH) in multiple myeloma (MM), which are important for improving care and outcomes.Methods: This was a retrospective study of real-world patients enrolled in a US insurance claims database (MM diagnosis, July 2018-December 2022) with linkage to a SDoH database, supplemented with mortality, provider affiliation (academic/community), and socioeconomically disadvantaged area databases. Treatment and outcomes were evaluated across SDoH domains: race/ethnicity, education level, transportation access, food insecurity, risky health behaviors, living in disadvantaged areas, healthcare needs, and ease of healthcare-systems engagement.Results: The study included 4768 patients (2295 and 2731 with care-setting and treatment data); median follow-up, 584 days. Patients treated in academic versus community settings were less likely to be food insecure and live in disadvantaged areas and had lower healthcare needs. Stem cell transplant was more common in White versus non-White patients, those with low versus high food insecurity and healthcare needs, and high versus low ease of healthcare-systems engagement. In multivariable analysis, high versus low disadvantaged areas (HR = 1.75) and medium versus low food insecurity (HR = 1.80) were associated with shorter overall survival.Conclusions: These findings indicate a need for improved access to care in the broader MM population.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1663-1673"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143997329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prognostic factors of long-term response to androgen receptor signaling inhibitors used as first-line treatment for mCRPC. 雄激素受体信号抑制剂作为一线治疗mCRPC的长期疗效的预后因素。

IF 3 4区医学

Future oncology Pub Date : 2025-06-01 Epub Date: 2025-04-28 DOI: 10.1080/14796694.2025.2497749

Antonello Veccia, Umberto Basso, Carlo Cattrini, Paola Ermacora, Marco Maruzzo, Martina Alberti, Cecilia Anesi, Davide Bimbatti, Massimiliano Cani, Veronica Crespi, Giovanni Farinea, Dzenete Kadrija, Stefania Kinspergher, Eleonora Lai, Ludovica Lay, Francesca Maines, Alessia Mennitto, Francesco Pierantoni, Alessandro Samuelly, Susanna Urban, Orazio Caffo, Consuelo Buttigliero

{"title":"Prognostic factors of long-term response to androgen receptor signaling inhibitors used as first-line treatment for mCRPC.","authors":"Antonello Veccia, Umberto Basso, Carlo Cattrini, Paola Ermacora, Marco Maruzzo, Martina Alberti, Cecilia Anesi, Davide Bimbatti, Massimiliano Cani, Veronica Crespi, Giovanni Farinea, Dzenete Kadrija, Stefania Kinspergher, Eleonora Lai, Ludovica Lay, Francesca Maines, Alessia Mennitto, Francesco Pierantoni, Alessandro Samuelly, Susanna Urban, Orazio Caffo, Consuelo Buttigliero","doi":"10.1080/14796694.2025.2497749","DOIUrl":"10.1080/14796694.2025.2497749","url":null,"abstract":"Aim: Androgen receptor signaling inhibitors (ARSI) demonstrated to be efficacious as first-line therapy for mCRPC. The present real-world study aimed to identify the characteristics of the long-term responders (LTR) patients to first-line ARSI.Methods: We retrospectively reviewed a consecutive series of 622 mCRPC patients treated with one ARSI as first line. Patients received standard doses of abiraterone (1000 mg daily plus prednisone 10 mg daily) or enzalutamide (160 mg daily) until progression. Patients with an ARSI exposure ≥ 36 months were considered as LTR.Results: We identified 99 LTR patients who were compared to 523 no-LTR patients. At the multivariable analysis, LTR patients showed younger age (p < 0.0001), longer time to mCRPC (p < 0.0001), higher baseline levels of hemoglobin (p = 0.007), lower baseline PSA levels (p = 0.03), longer PSA doubling time (p = 0.03), low number of bone metastases (p = 0.01), and receivedenzalutamide (p = 0.01). The median overall survival (OS) of LTR was 78.2 months (95% CI 72.3-84.1 months) vs 27.7 months of no-LTR (95% CI 25.9-29.6 months).Conclusions: Several clinical and biological factors allow to identify those patients with higher probability of becoming LTR to ARSI in first-line mCRPC setting.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1647-1653"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144012347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0